Evidence map›Paper›PMID 27151564›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2016

Improving paclitaxel pharmacokinetics by using tumor-specific mesoporous silica nanoparticles with intraperitoneal delivery.

Qiang Fu, Derek Hargrove, Xiuling Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Tumor-mesoporous silica nanoparticle interactions following intraperitoneal delivery for targeting peritoneal metastasis.Journal of controlled release : official journal of the Controlled Release Society · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Qiang FuDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, 06269, USA.
Derek HargroveDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, 06269, USA.
Xiuling LuDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, 06269, USA. Electronic address: xiuling.lu@uconn.edu.

Funding

Intraperitoneal Delivery of Targeted Nanoparticles for Metastatic Ovarian CancerR03CA184394 · NCI · UNIVERSITY OF CONNECTICUT STORRS · PI LU, XIULING · 2015 to 2016
$158k
NCI NIH HHS R03 CA184394
6 · The paper itself

Abstract

Mesoporous silica nanoparticles (MSNs) containing paclitaxel for intraperitoneal (i.p.) delivery were developed to exploit the tumor specific accumulation of these nanocarriers after i.p. injection and the slow release of paclitaxel from the MSNs. A 3.5-fold increase in tumor cellular drug uptake was observed for the paclitaxel-loaded MSNs compared with free paclitaxel. An in vivo study using xenograft mice bearing peritoneal human pancreatic carcinoma MIA PaCa-2 demonstrated that the MSN-paclitaxel formulation, compared to free paclitaxel, exhibited a 3.2-fold increase in peritoneal cavity residence time, slower absorption into the systemic circulation with one third systemic exposure, but a 6.5-fold increase in peritoneal tumor accumulation. Tissue distribution imaging showed significantly greater accumulation of fluorescent MSNs in tumor tissues compared to other peritoneal tissues. In conclusion, intraperitoneal administration of drug-containing MSNs was effective at reducing systemic exposure and increasing the peritoneal tumor accumulation of paclitaxel.

Indexed as

NanoparticlesSilicon DioxideAnimalsAntineoplastic Agents, PhytogenicDrug CarriersHumansMiceNeoplasmsPaclitaxelPorosityAntineoplastic Agents, PhytogenicDrug CarriersPaclitaxelSilicon DioxideIntraperitoneal therapyMesoporous silica nanoparticlesPaclitaxelPeritoneal cancerPharmacokinetics

Identifiers

PMID27151564
PMCPMC5115211

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.